Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma i...

A joint letter co-signed by the Royal Pharmaceutical Society, the British Medical Association, the Royal College of GPs, patient group National Voices and others has...

With last month’s $2.3 billion Japanese consumer health sale to Blackstone Group, Takeda has arguably achieved its $10 billion divestment goal. But the Japanese phar...

Squaring off against Pfizer in the next-gen pneumococcal vaccine field, Merck has posted two more positive phase 3 trials and now says it's planning an FDA filing ye...

In the hunt for a COVID-19 vaccine, no front-runner is moving as quickly as Pfizer and BioNTech's mRNA-based shot, which is scoping an October regulatory review. Des...

Six years ago, the French Competition Authority raided the local offices of Roche and Novartis in search of evidence of missteps in the way the companies were market...

Last month, Roche’s Tecentriq chalked up a surprising failure when used in tandem with chemotherapy paclitaxel in triple negative breast cancer (TNBC). The FDA has t...

wo-week programme to spark first pan-global debate on pharma’s 2020 transformations underway. Sessions will cover affordable medicines, ultra-rapid innovation, suppl...

With investigators recruiting participants for late-stage COVID-19 vaccine trials, officials are working behind the scenes at the federal, state and local levels to ...

After a surprise rejection from the FDA derailed Intercept’s plans to launch the first nonalcoholic steatohepatitis (NASH) drug, the company is cuttin...